NUCLIDIUM Secures CHF 79 Million in Series B Financing to Advance Copper-Based Theranostic Platform

NUCLIDIUM Announces Successful Completion of CHF 79 Million (€84 Million) Series B FinancingNUCLIDIUM today announced the successful completion of its Series B financing round, raising CHF 79 million (approximately €84 million). The company is a clinical-stage innovative drug developer focused on building an integrated theranostic platform based on copper (Cu) radionuclides.

This round of financing was jointly invested by professional institutions including Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, Bayern Kapital, Eurazeo, Vives Partners, and HLC (HighLight Capital), with continued participation from existing investors.

The proceeds from this financing round will be used to advance the clinical development of the company’s Cu-61/Cu-67 theranostic pipeline and to expand its global supply chain infrastructure for copper-based radiopharmaceuticals. The company will also continue to strengthen its international team and enhance strategic collaborations with hospitals and academic centers worldwide.

Dr. Leila Jaafar, CEO and Co-Founder of NUCLIDIUM, stated, “The company is advancing its lead pipeline candidates into the next phase of clinical trials, with indications covering metastatic prostate cancer, neuroendocrine tumors, and breast cancer. Our Cu-based theranostic technology enables seamless integration with hospital workflows, diagnostic and therapeutic services, and waste management systems, significantly enhancing the global accessibility of radiopharmaceuticals. Leveraging our breakthrough next-generation Cu radiopharmaceutical technology platform, we are accelerating the development of novel targeted therapies across a broader spectrum of cancer types.”

Nuclidium AG is a clinical-stage biotechnology company dedicated to developing next-generation copper-based radiopharmaceuticals for cancer diagnosis and treatment. By leveraging the theranostic radioisotope pair Cu-61 (for diagnosis) and Cu-67 (for therapy), the company has built a differentiated technology platform poised to overcome the bottlenecks of current radiodiagnostic and radiotherapeutic technologies. Operating in both Switzerland and Germany, Nuclidium AG integrates innovative chemistry, deep clinical expertise, and strategic manufacturing capabilities to deliver scalable, highly accessible, and clinically superior theranostic solutions to patients worldwide.